Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis.
Eur J Endocrinol
; 170(6): R253-62, 2014 Jun.
Article
em En
| MEDLINE
| ID: mdl-24616413
ABSTRACT
Bexarotene (Targretin), approved since 1999 as a second-line treatment for late stage cutaneous T-cell lymphomas, has been shown to induce significant hypothyroidism through TSH suppression. This review revisits, through a case report, mechanisms by which rexinoids repress the expression of TSHB gene as well as αTSH and TRH genes. It appears that rexinoids suppress TSH independently from tri-iodothyronine. Bexarotene also differently affects the gene expression of deiodinases 1 and 2 as well as the peripheral clearance of thyroxine. These data might open new ways of research on the potential interaction between thyroid axis and endogenous rexinoids.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Retinoides
/
Neoplasias Cutâneas
/
Tetra-Hidronaftalenos
/
Glândula Tireoide
/
Linfoma Cutâneo de Células T
/
Doenças do Sistema Endócrino
/
Antineoplásicos
Limite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Eur J Endocrinol
Assunto da revista:
ENDOCRINOLOGIA
Ano de publicação:
2014
Tipo de documento:
Article